REFERENCES
- Matthay K K, Villablanca J G, Seeger R C, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165–1173, [PUBMED], [CSA]
- Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999; 455: 59–62, [PUBMED], [CROSSREF], [CSA]
- Ross R A, Spengler B A, Biedler J L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983; 71: 741–747, [PUBMED], [CSA]
- Bian X, Opipari A W, Jr, Ratanaproeksa A B, Boitano A E, Lucas P C, Castle V P. Constitutively active NF kappa B is required for the survival of S-type neuroblastoma. J Biol Chem 2002; 277: 42144–42150, [PUBMED], [CROSSREF], [CSA]
- Wang Z Y. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 2001; 48(Suppl 1)S72–S76, [PUBMED], [CROSSREF], [CSA]
- Meister A, Anderson M E. Glutathione. Ann Rev Biochem 1983; 52: 711–760, [PUBMED], [CROSSREF], [CSA]
- Evens A M, Tallman M S, Gartenhaus R B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004; 28: 891–900, [PUBMED], [CROSSREF], [CSA]
- Ora I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000; 277: 179–185, [PUBMED], [CROSSREF], [CSA]
- Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432–5440, [PUBMED], [CSA]
- Hyun Park W, Hee Cho Y, Won Jung C, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230–235, [PUBMED], [CROSSREF], [CSA]
- Davison K, Mann K K, Miller W H, Jr. Arsenic trioxide: mechanisms of action. Semin Hematol 2002; 39: 3–7, [PUBMED], [CROSSREF], [CSA]
- Qian Y, Castranova V, Shi X. New perspectives in arsenic-induced cell signal transduction. J Inorg Biochem 2003; 96: 271–278, [PUBMED], [CROSSREF], [CSA]
- Huang M J, Hsieh R K, Lin C P, Chang I Y, Liu H J. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 2002; 43: 2191–2199, [PUBMED], [CROSSREF], [CSA]
- Park W H, Seol J G, Kim E S, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065–3071, [PUBMED], [INFOTRIEVE], [CSA]
- Jing Y, Dai J, Chalmers-Redman R M, Tatton W G, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111, [PUBMED], [CSA]
- Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 2004; 64: 108–116, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Akao Y, Yamada H, Nakagawa Y. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000; 37: 53–63, [PUBMED], [INFOTRIEVE], [CSA]
- Yi J, Gao F, Shi G, et al. The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 2002; 7: 209–215, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gao F, Yi J, Yuan J Q, Shi G Y, Tang X M. The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species. Cell Res 2004; 14: 81–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Park J W, Choi Y J, Jang M A, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001; 286: 726–734, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Munoz J P, Sanchez J R, Maccioni R B. Regulation of p27 in the process of neuroblastoma N2A differentiation. J Cell Biochem 2003; 89: 539–549, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang C Y, Cusack J C, Jr, Liu R, Baldwin A S, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999; 5: 412–417, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen F, Lu Y, Zhang Z, et al. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001; 276: 11414–11419, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]